Krystal Biotech Inc Stock News

PITTSBURGH, March 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that results from the

PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed resul

PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present l

PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present lat

Krystal Biotech (KRYS) said it reached an agreement with PeriphaGen to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020

Krystal Biotech (NASDAQ: KRYS ) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Krystal Biotech missed estimated earnings by 28.77%, reporting an EPS of … Full story available on Benzinga.com

Krystal Biotech press release (KRYS): Q4 GAAP EPS of -$3.13 misses by $2.40.Cash, cash equivalents and investments totaled $502.5 million on December 31, 2021, compared to…

PITTSBURGH, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal” or the "Company") (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key op

PITTSBURGH, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal” or the "Company") (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational updates for the fourth quarter and year ending December 31, 2021.

Steven Cohen (Trades, Portfolio), leader of Point72 Asset Management, disclosed earlier this week he increased his stake in IDEAYA Biosciences Inc. ( IDYA , Financial) by 52.12%.

Krystal produced excellent phase 3 data.

During the last session, Krystal Biotech Inc. (NASDAQ:KRYS)s traded shares were 0.3 million, with the beta value of the company hitting 0.99. At the end of the trading day, the stocks price was $60.86, reflecting an intraday loss of -6.84% or -$4.47. The 52-week high for the KRYS share is $102.99, that puts it down Is Krystal Biotech Inc. (NASDAQ: KRYS) Still A Loss Stock Despite Being Down -12.99% YTD? Read More »

For these two companies, the rewards could end up outweighing the risks.

For these two companies, the rewards could end up outweighing the risks.

Krystal Biotech Inc (NASDAQ: KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities. The Krystal Biotech Analyst: Geoff Meacham initiated cove